TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06252610
Drug: Contrast Media, Magnetic Resonance
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected.
Study: NCT06425120
Drug: Xuesaitong Soft Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
Study: NCT06425120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant in the placebo group will take matching placebo.
Study: NCT06569537
Drug: BLT
Normalized name: BLT-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Study: NCT04874038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
Study: NCT06448780
Drug: Caffeine citrate 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study: NCT06448780
Drug: Caffeine citrate 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study: NCT06431919
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin fixed dose of 20 mg per day
Study: NCT06189040
Drug: BNT162b2 30µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular administration of 30µg
Study: NCT06189040
Drug: BNT162b2 20µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular administration of 20µg
Study: NCT04964089
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT05211024
Drug: Penicillin G Benzathine
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
Study: NCT05640934
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
Study: NCT05640934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
Study: NCT06535087
Drug: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.
Study: NCT05729074
Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study: NCT05729074
Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
Study: NCT05729074
Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study: NCT05729074
Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study: NCT05729074
Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study: NCT05729074
Drug: IN-A002 Ointment 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
Study: NCT05729074
Drug: IN-A002 Ointment 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
Study: NCT05729074
Drug: Elidel Cream 1% (pimecrolimus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
Study: NCT05923060
Drug: Topical Aminolevulinate
Normalized name: aminolevulinate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Levulan Kerastick is applied to actinic keratoses.
Study: NCT04857359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo tablet
Study: NCT06074094
Drug: Control Test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
Study: NCT06532682
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor
Study: NCT05401292
Drug: Isopropyl Alcohol 70% Topical Application Solution
Normalized name: Isopropyl Alcohol 70% Topical application Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: First aid antiseptic
Study: NCT04993690
Drug: LP-168 tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
Study: NCT06691269
Drug: Topical Benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Benzocaine at injection site to reduce discomfort of local infiltration
Study: NCT06687772
Drug: Anthracycline-based induction chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care, not dictated by protocol.
Study: NCT05933291
Drug: steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate- or high-dose steroids
Study: NCT06386653
Drug: Diagnostic injection of [123I]I-DARPIN-Ec1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous injection of \[123I\]I-DARPIN-Ec1
Study: NCT02233829
Drug: Brain Dopamine Reactivity
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
Study: NCT06619392
Drug: HRS-2129 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-2129 Placebo
Study: NCT06391372
Drug: estriol cream
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
Study: NCT04735185
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
Study: NCT04735185
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
Study: NCT05182203
Drug: biologic/targeted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors or the JAK inhibitors
Study: NCT05279937
Drug: Dextrose 50% Intravenous Solution
Normalized name: Dextrose 50% Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
Study: NCT05519839
Drug: Influenza Vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
Study: NCT00000681
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06266923
Drug: SPH6516 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
Study: NCT06681389
Drug: NP-201 acetate injection (Part A)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
Study: NCT06681389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered across Part A and Part B
Study: NCT06681181
Drug: GSK4528287
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4528287 will be administered.
Study: NCT06681181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05064345
Drug: HB0034
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Study: NCT05064345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palcebo
Study: NCT04752696
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT04752696
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05298085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be administered intranasally daily for 12 weeks.
Study: NCT05982522
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally taken once daily
Study: NCT05995912
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (with or without food)
Study: NCT05294640
Drug: 0.9% Bacteriostatic Local Anesthetic Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Study: NCT05294640
Drug: 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Study: NCT06202885
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy
Study: NCT06671392
Drug: DWC202405
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20mg, 1 tablet, Oral, Once a day
Study: NCT06671392
Drug: DWC202405, DWC202314
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20mg + 1.5mg, 1 tablet, Oral, Once a day
Study: NCT06671392
Drug: DWC202405, DWC202314P
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20mg + 1.5mg, 1 tablet, Oral, Once a day
Study: NCT06671392
Drug: DWC202313, DWC202314
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/40mg + 1.5mg, 1 tablet, Oral, Once a day
Study: NCT06671392
Drug: DWC202313, DWC202314P
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/40mg + 1.5mg, 1 tablet, Oral, Once a day
Study: NCT06615479
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06345755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution or Suspension for oral administration.
Study: NCT06197139
Drug: [177Lu]Lu-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
Study: NCT06681766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
Study: NCT06679816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative placebo Reduction Therapy
Study: NCT06681441
Drug: QRL-101 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Study: NCT06681441
Drug: QRL-101 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Study: NCT06681441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Study: NCT05583071
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT05214768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05248893
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT04721977
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 administered BID via oral tablet
Study: NCT05652751
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Study: NCT04391231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (SyrSpend SF only)
Study: NCT05643066
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline was intravenously injected first.
Study: NCT06182865
Drug: Ga-68 Dolacga Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
Study: NCT04564833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT05093517
Drug: Placebo Subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for REMD-477 to which subjects will be randomized 1:2.
Study: NCT06465069
Drug: LY4052031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT06189170
Drug: KP405
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT06189170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05104983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06619483
Drug: BAY3018250 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT06619483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BAY3018250
Study: NCT06619483
Drug: BAY3018250 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT06107062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT06619847
Drug: HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT06619847
Drug: Placebo (matched to VX-993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-993 for oral administration.
Study: NCT06619847
Drug: Placebo (matched to HB/APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT04713358
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately Intravenous injection of normal saline 1ml after surgery
Study: NCT06251050
Drug: Plcacebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
Study: NCT06672016
Drug: Transdermal system containing progestin
Normalized name: CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-130A-01 transdermal system, patch to be used for female contraception
Study: NCT05627856
Drug: GNC-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06598007
Drug: CT3001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
Study: NCT06592482
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water.
Study: NCT06661746
Drug: Multimodal IV analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal IV analgesia of lidocaine, ketamine and MS
Study: NCT05662358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo weekly
Study: NCT04967755
Drug: Jing-Si-Herbal-Tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
Study: NCT00001101
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06531720
Drug: Choline Salicylate 8.7 % Oral Gel
Normalized name: choline salicylate 8.7 % Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical preparation applied on oral mucosa lesion containing, ethanol-based
Study: NCT06535412
Drug: Placebo + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection of Placebo
Study: NCT05879744
Drug: CLN-978
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19xCD3 T cell engager
Study: NCT04826692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
Study: NCT06625775
Drug: BBO-10203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD
Study: NCT06209320
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administer to eyes
Study: NCT06683846
Drug: Ivocizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT05471947
Drug: 15% Trichloroacetic acid + 3% glycolic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
Study: NCT06685289
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
Study: NCT05190341
Drug: Ibuprofen 800 mg oral
Normalized name: IBUPROFEN 800 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 hour before HSG
Study: NCT05190341
Drug: Ketorolac 30mg oral
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 hour before HSG
Study: NCT06686537
Drug: Estradiol Patches
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol patched will be worn for 7 days.
Study: NCT06686797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution/suspension
Study: NCT06691828
Drug: NX-5948
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-5948 will be given once by IV and then given once by mouth.
Study: NCT06628310
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion; IV Injection
Study: NCT06628310
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion; IV Injection